<DOC>
	<DOCNO>NCT02616029</DOCNO>
	<brief_summary>This study evaluate efficacy elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide ( E/C/F/TAF ) fix dose combination ( FDC ) switch stable regimen consist emtricitabine/tenofovir disoproxil fumarate ( FTC/TDF ) abacavir/lamivudine ( ABC/3TC ) plus third antiretroviral agent participant harbor archive nucleoside/nucleotide reverse transcriptase inhibitor ( NRTI ) resistance mutation M184V and/or M184I HIV-1 reverse transcriptase .</brief_summary>
	<brief_title>Switching Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide ( E/C/F/TAF ) Fixed Dose Combination ( FDC ) Virologically-Suppressed HIV-1 Infected Adults Harboring Archived Isolated NRTI Resistance Mutation M184V/M184I</brief_title>
	<detailed_description />
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<criteria>Key Documented historical genotype report show M184V and/or M184I ( mixture acceptable ) reverse transcriptase . Individuals must primary integrase strand transfer inhibitor ( INSTI ) primary protease inhibitor ( PI ) resistance mutation present historical genotype ; nonnucleoside reverse transcriptase inhibitor ( NNRTI ) mutation allow . Proviral DNA test must additional exclusion resistance mutation PIs , NRTIs INSTIs Part 1 ( first 50 individual ) : Historical genotype report must show M184V and/or M184I reverse transcriptase WITHOUT NRTI resistance mutation ( include thymidine analogueassociated mutation ( TAMs ) [ TAMs : M41L , D67N , K70R , L210W , T215Y/F , K219Q/E/N/R ] , K65R , T69 insertion Q151M mutation complex [ A62V , V75I , F77L , F116Y , Q151M ] Part 2 ( interim efficacy review 50 individual ) : Historical genotype report must show M184V and/or M184I reverse transcriptase WITH WITHOUT one two thymidine analogueassociated mutation ( TAMs ) [ TAMs : M41L , D67N , K70R , L210W , T215Y/F , K219Q/E/N/R ] . Evidence K65R , K70E , T69 insertion and/or Q151M mutation complex [ A62V , V75I , F77L , F116Y , Q151M ] eligible Currently receive antiretroviral regimen consist FTC/TDF ABC/3TC combination one third antiretroviral agent ≥ 6 consecutive month precede screen visit Documented plasma HIV1 RNA level &lt; 50 copies/mL ≥ 6 month precede screen visit Plasma HIV1 RNA level &lt; 50 copies/mL screen visit Estimated glomerular filtration rate ( GFR ) ≥ 30 mL/min accord CockcroftGault formula creatinine clearance A female individual eligible enter study confirm : pregnant nonchildbearing potential stop menstruate ≥ 12 month childbearing potential agrees utilize protocol specify method contraception nonheterosexually active practice sexual abstinence screen throughout duration study treatment 30 day follow discontinuation study drug Male individual must agree use protocol specify method ( ) contraception heterosexual intercourse nonheterosexually active , practice sexual abstinence screen throughout study period 30 day follow last study drug dose Male individual must agree refrain sperm donation first dose least 30 day last study drug dose Key Individuals evidence previous virologic failure PI/r INSTIbased regimen ( without resistance either class ARV ) . Individuals may evidence prior virologic failure NNRTI plus 2 NRTIbased regimen Individuals current PI/rbased regimen evidence previous use approve experimental integrase strand transfer inhibitor ( INSTI ) ( length time ) Hepatitis C infection would require therapy study Hepatitis B surface antigen ( HBsAg ) positive Individuals clinical evidence decompensated cirrhosis ( e.g. , ascites , encephalopathy , variceal bleeding , etc . ) Have implant defibrillator pacemaker A history malignancy within past 5 year ( prior screen ) ongoing malignancy cutaneous Kaposi 's sarcoma ( KS ) , basal cell carcinoma , resect , non invasive cutaneous squamous carcinoma . Individuals cutaneous KS eligible , must receive systemic therapy KS within 30 day Day 1 must anticipate require systemic therapy study Active , serious infection ( HIV1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior Day 1 NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>